Press Room

Continuous Manufacturing of Oral Solid Dosage Forms

Start
Tuesday, April 16, 2024
End
Thursday, April 18, 2024
Location: Portugal
Continuous Manufacturing of Oral Solid Dosage Forms_Hovione

Continuous manufacturing holds the promise of improved efficiency, enhanced quality, greater operational flexibility and accelerated development. At Hovione we are proud to be at the forefront of this industry transition and excited to join leading individuals from industry, academia and regulatory agencies at the ECA Conference on “Continuous Manufacturing of Oral Solid Dosage Forms”. 

Register today

and take advantage of the unique opportunity to visit Hovione's cutting-edge labs and continuous tableting manufacturing facilities in Lisbon, Portugal 

 

The objective of this event is to share the practical experience and the potential of continuous manufacturing for oral solid dosage forms, also known as Continuous Tableting:

  • Regulatory Requirements
  • Industry Experience
  • Technological Opportunities
  • Latest research

Speakers

  • Selma Celikovic, RCPE
  • Prof Dr Alastair Florence, CMAC
  • Joshua Hanson, Eli Lilly
  • Dr Doug Hausner, Thermofisher Scientific
  • Dr Jim Holman, GEA
  • Dr Adrian Kape, Glatt
  • Dr Sau (Larry) Lee, FDA
  • Prof Dr Jim Litster, University of Sheffield
  • Dr Robert Meyer, MSD
  • Dr José Luís Santos, Hovione
  • Wayne Sinclair, TEVA
  • Jan Verelst, Siemens

More about the Conference, Speakers and Programme

More about Hovione Site Visit:
As part of the conference, registered participants will have a unique opportunity to visit Hovione's cutting-edge labs and manufacturing facilities in Lisbon, where research, development, and manufacturing activities take place.

In the labs, participants will gain access to Particle Engineering facilities, explore some of the most advanced analytical PAT tools, and get a close look at the specialized equipment used in continuous tableting development. They will also have the chance to observe analytical and process development operations in an engaging hands-on workshop, guided by Hovione experts.

During the visit to the manufacturing facilities, participants will witness a state-of-the-art facility in action, showcasing a continuous direct compression production unit. Additionally, they will have the opportunity to see and compare with an equivalent batch process.
Please note that availability for this exclusive site visit is limited, so securing your spot early is highly recommended to ensure you don't miss out on this opportunity to experience Pharmaceutical innovation at Hovione.

  • We provide bus transfer from the conference hotel to the Hovione sites. After the site visit there will be transfers to the airport and back to the conference hotel.
  • Due to competition reasons, individual participants may be excluded from the site visit
  • Participants are required to sign a Confidential Disclosure Agreement (CDA) before entering Hovione sites

More about the ECA Academy:
The ECA Academy is the educational organisation established by the ECA Foundation. It develops and organises a wealth of international education courses, conferences (also as part of a GMP Certification Programme) and webinars around GMP and regulatory compliance, picking up emerging GMP challenges and currently discussed subjects. While courses and webinars are designed to provide continuous education for GMP professionals in production, quality control, quality assurance etc, European conferences are organised as discussion forums on new trends and developments.

If you have any questions about the Conference:
Tel.: +49 (0)6221 / 84 44 0 
www.gmp-compliance.org

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026